BrainCool AB (publ)
BrainCool AB (publ) is a Swedish medical device company developing therapeutic cooling systems for cardiac arrest, stroke, and chemotherapy-induced oral mucositis, selling through direct hospital sales and a ZOLL Medical distribution partnership across Europe and the United States.
- Company typePublic
- Founded2014
- HeadquartersLund, Sweden
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What BrainCool AB (publ) does
BrainCool AB (publ) is a Swedish medical device company headquartered at Medicon Village in Lund that develops, markets, and sells therapeutic cooling systems for three clinical indications: post-cardiac arrest care, acute ischemic stroke, and chemotherapy-induced oral mucositis. The company's core technology is Targeted Temperature Management (TTM), delivered through three products: the BrainCool System (branded IQool System in the United States), a surface cooling platform using three independent anatomical zones (head/neck, thighs, torso) with soft silicone pads prefilled with non-toxic BC COOL and a closed-loop control unit maintaining patient temperature between 33°C and 38.5°C; RhinoChill, a portable battery-powered transnasal evaporative cooling device that sprays coolant into the nasal cavity for rapid brain cooling (demonstrated 2.6°C brain temperature reduction within 60 minutes); and Cooral, an oral cryotherapy mouthpiece system for mucositis prevention. The products are CE marked and the BrainCool/IQool System is FDA 510(k) cleared.
The company operates a B2B enterprise model selling capital equipment and consumables to hospitals, intensive care units, stroke centers, emergency medical services, and oncology departments. Distribution is split between direct hospital sales in Europe and an international distribution partnership with ZOLL Medical Corporation, which the company identifies as the source of significant currency exposure in revenue recognition. Clinical adoption is supported by a substantial evidence base including the PRINCESS2 trial (920 patients across 8 European countries) and the COTTIS2 trial (400+ patients across 5 German sites), with academic partnerships including Karolinska Institutet and University Hospital of Freiburg. BrainCool is publicly listed on Nasdaq First North with 394.9 million shares outstanding; the largest shareholder is Chairman Anders Hallberg at 18.95%. The firm underwent a leadership refresh in 2024-2026, installing a new CEO, COO, Head of Distribution & Sales, and CTO, alongside board additions from large-cap medtech firms, signaling a transition toward commercial scaling.
BrainCool AB (publ) firmographics
Firmographics- Name
- BrainCool AB (publ)
- Legal name
- BrainCool AB (publ)
- Website
- https://braincool.se
- Company type
- Public
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BrainCool AB (publ) is a Swedish medical device company developing therapeutic cooling systems for cardiac arrest, stroke, and chemotherapy-induced oral mucositis, selling through direct hospital sales and a ZOLL Medical distribution partnership across Europe and the United States.
- Ownership category
- akta.pro rank
BrainCool AB (publ) industry classification
Industry- Product category
- Medical Cooling Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- akta.pro primary industry
- Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)
Keywords
Where BrainCool AB (publ) is headquartered
LocationHeadquarters
- HQ city
- Lund
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
BrainCool AB (publ) business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Others
Revenue model
- Medical Device Sales: Sale of medical cooling systems (BrainCool, RhinoChill, Cooral) to hospitals, healthcare providers, and EMS systems. Products include devices and associated consumables/pads.
- Distribution Partnership (ZOLL): Partnership with ZOLL for distribution of temperature management products, which creates currency exposure in revenue recognition due to international sales.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
BrainCool AB (publ) product offering
Product offeringCore offering
BrainCool AB develops, manufactures, and sells medical cooling systems for targeted temperature management across three indications: post-cardiac arrest care, ischemic stroke, and chemotherapy-induced oral mucositis. Its product portfolio includes the BrainCool System (surface cooling with three independent anatomical zones), the RhinoChill System (portable transnasal evaporative brain cooling for pre-hospital and in-hospital use), and the Cooral System (oral cryotherapy for mucositis prevention).
Product overview
BrainCool AB (publ) is a medical device company offering three distinct therapeutic cooling products. The BrainCool™ System (IQool™ System in the US) provides surface cooling with three anatomical zones and closed-loop temperature control between 33°C-38.5°C. The RhinoChill® System delivers rapid transnasal evaporative brain cooling via nasal catheter. The Cooral® System provides oral cryotherapy for mucositis prevention. The combination of BrainCool™ and RhinoChill® Systems provides the only comprehensive care solution from pre-hospital to patient discharge, while Cooral® addresses oncology supportive care.
Differentiator
Problem solved
Functional benefit
Brands
- BrainCool System: Surface cooling system for targeted temperature management (branded as IQool System in the United States)
- Cooral System
- RhinoChill System
Products and services
- BrainCool System Surface cooling temperature management system that monitors and controls an adult patient's temperature between 33C to 38.5C using three independent anatomical zones (head/neck, thighs, torso) with soft silicone pads and automated closed-loop heat exchange. CE marked and FDA 510(k) approved. Branded as IQool System in the United States. Intended for hospital ICUs and stroke centers.
- RhinoChill System Portable, battery-powered transnasal evaporative cooling system that achieves rapid brain cooling by spraying coolant into the patient's nostrils via catheter. Uses compressed air/oxygen to vaporize coolant against the nasal cavity upper surface, achieving 2.6C brain temperature reduction within 60 minutes. Clinically validated through PRINCE and PRINCESS studies. Intended for pre-hospital EMS and in-hospital cardiac arrest and stroke care.
- Cooral System Cryotherapy oral mucositis prevention system using a mouthpiece to deliver controlled cooling to the oral cavity, constricting blood vessels and reducing chemotherapy drug damage to mouth tissues. Developed by CoolPrevent AB (a wholly owned subsidiary) to improve quality of life during cancer treatment. Intended for oncology departments and cancer treatment centers.
Quantifiable outcome
- 2.6 degrees C brain temperature reduction within 60 minutes
- +3 more outcomes
Companies that use BrainCool AB (publ)
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
BrainCool AB (publ) technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
BrainCool AB (publ) partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core.
- Karolinska InstitutetcoreAcademic partner leading the PRINCESS2 clinical trial for RhinoChill in cardiac arrest. Dr Per Nordberg serves as principal investigator from Karolinska Institutet.
- University Hospital of FreiburgcoreClinical trial partner for COTTIS2 trial evaluating RhinoChill in stroke patients. Professor Dr Jurgen Bardutzky serves as principal investigator.
- ZOLL Medical CorporationcoreDistribution partnership with ZOLL for temperature management products. The partnership creates significant currency exposure via international sales, as noted in CEO communications. ZOLL distributes BrainCool's temperature management solutions internationally.
- BrainCool InccoreFully owned US subsidiary of BrainCool AB. Handles US market operations and FDA-approved product distribution (IQool System).
- CoolPrevent ABcoreFully owned Swedish subsidiary of BrainCool AB. Developer of Cooral System for oral mucositis prevention.
- IQool Technologies ABcoreFully owned Swedish subsidiary of BrainCool AB. Holder of IQool System trademark (US brand name for BrainCool System).
- BeneChill ABcoreFully owned Swedish subsidiary of BrainCool AB. Part of the group structure for temperature management products.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
BrainCool AB (publ) competitors and assessment
Company assessmentDirect peers
- ZOLL Medical Corporation: ZOLL manufactures Thermogard XP, a leading intravascular temperature management system for cardiac arrest and stroke, and is BrainCool's distribution partner — making it both the most direct competitor and primary channel partner.
- Dignitana AB: Swedish MedTech company developing DigniCap scalp cooling for chemotherapy-induced alopecia. Closely comparable as a Nordic MedTech in cryotherapy/cooling adjacent to oncology supportive care, and shares talent lineage with BrainCool (Christian Strand, Hakan Hummet).
- PolarCool AB: Swedish MedTech company specializing in head and neck cooling for sports-related concussion. BrainCool's Head of Distribution & Sales Christian Strand previously served as interim CEO of PolarCool, making it a closely related Nordic cooling-MedTech peer.
Emerging players
- Penumbra, Inc. Specialized neurovascular device company with the Penumbra System for stroke thrombectomy. Competes with BrainCool's stroke-focused RhinoChill for ischemic stroke treatment protocols and hospital stroke-center budgets.
- Inspira Technologies: Emerging player in critical care respiratory and patient monitoring. Comparable as a small-cap, clinically-evidence-driven MedTech targeting ICU and emergency medicine use cases that overlap with BrainCool's TTM deployments.
Broad incumbents
- Becton, Dickinson and Company (BD): BD acquired the Medivance/Bard business that makes the Arctic Sun surface cooling system, the dominant non-invasive TTM platform. Arctic Sun directly competes with BrainCool's IQool System in hospitals.
- Medtronic plc: Global MedTech incumbent with a broad neurovascular and stroke intervention portfolio (e.g., Solitaire stent retriever) that competes for the same stroke-center budgets as RhinoChill.
- Stryker Corporation: Large diversified MedTech with neurovascular, emergency, and ICU product lines. Serves the same emergency department and stroke-center procurement channels as BrainCool.
Others
- BONESUPPORT AB: Swedish orthobiologics MedTech listed on Nasdaq Stockholm. Comparable as a publicly listed Nordic MedTech at a similar stage, with direct talent overlap via BrainCool board member Annelie Aava Vikner (EVP Global Marketing at BONESUPPORT).
- Atos Medical AB: Swedish MedTech specializing in laryngectomy and tracheostomy care, now part of Coloplast. Adjacent Nordic MedTech peer with shared talent lineage (BrainCool COO Jon Berg was Development Manager at Atos Medical).
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
BrainCool AB (publ) social profiles
Digital presenceBrainCool AB (publ) compliance and trust
Trust signalCompliance3 records
BrainCool AB (publ) financial estimates
Financial estimateRevenue estimate
Valuation estimate
BrainCool AB (publ) leadership team
Management profileNumber of profiles
Profiles10 records
BrainCool AB (publ) subsidiaries and ownership
Company hierarchySubsidiaries4 records
BrainCool AB (publ) funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BrainCool AB (publ) M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BrainCool AB (publ)
What does BrainCool AB (publ) do?
BrainCool AB develops, manufactures, and sells medical cooling systems for targeted temperature management across three indications: post-cardiac arrest care, ischemic stroke, and chemotherapy-induced oral mucositis. Its product portfolio includes the BrainCool System (surface cooling with three independent anatomical zones), the RhinoChill System (portable transnasal evaporative brain cooling for pre-hospital and in-hospital use), and the Cooral System (oral cryotherapy for mucositis prevention).
Is BrainCool AB (publ) a public or private company?
BrainCool AB (publ) is a public company. It is classified as public and is currently operating.
When was BrainCool AB (publ) founded?
BrainCool AB (publ) was founded in 2014. It employs 11 to 50 people.
Where is BrainCool AB (publ) based?
BrainCool AB (publ) is headquartered in Lund, Sweden, in the Europe region.
How does BrainCool AB (publ) make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are distribution Partnership (ZOLL).
Who are BrainCool AB (publ)'s main competitors?
Direct peers on record are ZOLL Medical Corporation, Dignitana AB and PolarCool AB. Emerging players are Penumbra, Inc. and Inspira Technologies. Broad incumbents are Becton, Dickinson and Company (BD), Medtronic plc and Stryker Corporation. Others are BONESUPPORT AB and Atos Medical AB.
Does BrainCool AB (publ) have an API?
No public API is recorded for BrainCool AB (publ).
What industry is BrainCool AB (publ) in?
BrainCool AB (publ)'s product category is Medical Cooling Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices. Its NAICS code is 334510.